Drug-eluting coronary stents are associated with disturbing new findings regarding the risk of late thrombosis, fueling controversy over their safety despite preventing restenosis.
Do drug-eluting coronary stents increase the risk of late thrombosis despite preventing restenosis?
Discusses the controversy and emerging concerns regarding late thrombosis risk associated with drug-eluting stents.
In September, at the World Cardiology Congress in Barcelona, Donald Baim, a cardiologist who is the new chief medical and scientific officer of Boston Scientific, was talking to a reporter when he mentioned disturbing new findings regarding the risk of late thrombosis associated with drug-eluting coronary stents. The revelation fueled a newly ignited controversy. Lauded as a means of preventing restenosis, drug-eluting stents have been implanted in nearly 6 million patients worldwide since they were introduced 3 years ago. The Food and Drug Administration (FDA) responded to the controversy by issuing a statement that drug-eluting stents are “safe and effective . . .
Miriam Shuchman (Wed,) conducted a editorial in Coronary artery disease. Drug-eluting coronary stents was evaluated. Drug-eluting coronary stents are associated with disturbing new findings regarding the risk of late thrombosis, fueling controversy over their safety despite preventing restenosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: